Tilianin attenuates MPP<sup>+</sup>‑induced oxidative stress and apoptosis of dopaminergic neurons in a cellular model of Parkinson's disease

Li,Jie; Xu,Sui

doi:10.3892/etm.2022.11223

Tilianin attenuates MPP⁺‑induced oxidative stress and apoptosis of dopaminergic neurons in a cellular model of Parkinson's disease

Authors:
- Jie Li
- Sui Xu
View Affiliations

Affiliations: Department of Clinical Medicine, Suzhou Vocational Health College, Suzhou, Jiangsu 215009, P.R. China, Department of Traditional Chinese Medicine, Huamu Community Health Service Center, Shanghai 200120, P.R. China
Published online on: February 17, 2022 https://doi.org/10.3892/etm.2022.11223
Article Number: 293
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The flavonoid tilianin is derived from the leaves of Dracocephalum moldavica L. amiales and has been proven to serve a neuroprotective role in cerebral ischemia. Therefore, the aim of the present study was to determine whether tilianin could prevent oxidative stress and the apoptosis of dopaminergic neurons in Parkinson's disease (PD). The dopaminergic neuron MES23.5 cell line was treated with 1‑methyl‑4‑phenylpyridinium (MPP+) to construct a PD cell model. Following pretreatment with tilianin, the Cell Counting Kit‑8 assay was used to assess cell viability. The protein and mRNA expression levels of tyrosine hydroxylase were determined using immunofluorescence, reverse transcription‑quantitative PCR (RT‑qPCR) and western blotting. mRNA and protein expression levels of inflammatory cytokines IL‑6, IL‑1β and TNF‑α and oxidative stress‑related enzymes manganese superoxide dismutase and catalase were also quantified using RT‑qPCR and western blotting, respectively. Cell apoptotic rate was analyzed using the TUNEL assay and the expressions of apoptosis‑related proteins Bcl‑2, Bax and cleaved caspase‑3 were detected by western blotting. MAPK signaling pathway‑related protein expression levels were assessed via western blotting in MPP⁺‑stimulated MES23.5 cells with or without tilianin pretreatment. Tilianin was demonstrated to exert no cytotoxic effects on MES23.5 cells and was able to prevent MPP^₊‑induced reductions in cell viability. Pretreatment with tilianin also inhibited MPP⁺‑induced inflammatory cytokine secretion, oxidative stress and apoptosis of MES23.5 cells. In addition, the protein expression levels of MAPK signaling pathway‑related proteins were upregulated by MPP⁺, whereas pretreatment with tilianin downregulated these in a dose‑dependent manner. The results of the present study indicated that tilianin may exert anti‑inflammatory and antioxidant effects and inhibit the MAPK signaling pathway, which may ameliorate injury to dopaminergic neurons induced by PD.

View Figures

View References

1	Wickremaratchi MM, Ben-Shlomo Y and Morris HR: The effect of onset age on the clinical features of Parkinson's disease. Eur J Neurol. 16:450–456. 2009.PubMed/NCBI View Article : Google Scholar
2	Rizek P, Kumar N and Jog MS: An update on the diagnosis and treatment of Parkinson disease. CMAJ. 188:1157–1165. 2016.PubMed/NCBI View Article : Google Scholar
3	Cui L, Hou NN, Wu HM, Zuo X, Lian YZ, Zhang CN, Wang ZF, Zhang X and Zhu JH: Prevalence of Alzheimer's disease and parkinson's disease in China: An updated systematical analysis. Front Aging Neurosci. 12(603854)2020.PubMed/NCBI View Article : Google Scholar
4	Tang Q, Wang C, Wu W, Cao Y, Chen G and Lu J: China should emphasize key issues inherent in rational medication management for the elderly. Biosci Trends. 15:262–265. 2021.PubMed/NCBI View Article : Google Scholar
5	Ng JSC: Palliative care for Parkinson's disease. Ann Palliat Med. 7:296–303. 2018.PubMed/NCBI View Article : Google Scholar
6	Armstrong MJ and Okun MS: Diagnosis and treatment of Parkinson disease: A review. JAMA. 323:548–560. 2020.PubMed/NCBI View Article : Google Scholar
7	Pezzoli G and Zini M: Levodopa in Parkinson's disease: From the past to the future. Expert Opin Pharmacother. 11:627–635. 2010.PubMed/NCBI View Article : Google Scholar
8	Vasta R, Nicoletti A, Mostile G, Dibilio V, Sciacca G, Contrafatto D, Cicero CE, Raciti L, Luca A and Zappia M: Side effects induced by the acute levodopa challenge in Parkinson's disease and atypical parkinsonisms. PLoS One. 12(e0172145)2017.PubMed/NCBI View Article : Google Scholar
9	Trist BG, Hare DJ and Double KL: Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease. Aging Cell. 18(e13031)2019.PubMed/NCBI View Article : Google Scholar
10	Bai L, Li X, He L, Zheng Y, Lu H and Li J, Zhong L, Tong R, Jiang Z, Shi J and Li J: Antidiabetic potential of flavonoids from traditional Chinese medicine: A review. Am J Chin Med. 47:933–957. 2019.PubMed/NCBI View Article : Google Scholar
11	Wang ZY, Liu JG, Li H and Yang HM: Pharmacological effects of active components of chinese herbal medicine in the treatment of Alzheimer's disease: A review. Am J Chin Med. 44:1525–1541. 2016.PubMed/NCBI View Article : Google Scholar
12	Akanda MR, Uddin MN, Kim IS, Ahn D, Tae HJ and Park BY: The biological and pharmacological roles of polyphenol flavonoid tilianin. Eur J Pharmacol. 842:291–297. 2019.PubMed/NCBI View Article : Google Scholar
13	Song WY, Song YS, Ryu HW, Oh SR, Hong J and Yoon DY: Tilianin inhibits MUC5AC expression mediated via down-regulation of EGFR-MEK-ERK-Sp1 signaling pathway in NCI-H292 human airway cells. J Microbiol Biotechnol. 27:49–56. 2017.PubMed/NCBI View Article : Google Scholar
14	Jiang H, Fang J, Xing J, Wang L, Wang Q, Wang Y, Li Z and Liu R: Tilianin mediates neuroprotection against ischemic injury by attenuating CaMKII-dependent mitochondrion-mediated apoptosis and MAPK/NF-κB signaling. Life Sci. 216:233–245. 2019.PubMed/NCBI View Article : Google Scholar
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
16	Cacabelos R: Parkinson's disease: From pathogenesis to pharmacogenomics. Int J Mol Sci. 18(551)2017.PubMed/NCBI View Article : Google Scholar
17	Wakabayashi K, Tanji K, Odagiri S, Miki Y, Mori F and Takahashi H: The Lewy body in Parkinson's disease and related neurodegenerative disorders. Mol Neurobiol. 47:495–508. 2013.PubMed/NCBI View Article : Google Scholar
18	Cao M, Wu Y, Ashrafi G, McCartney AJ, Wheeler H, Bushong EA, Boassa D, Ellisman MH, Ryan TA and De Camilli P: Parkinson Sac domain mutation in synaptojanin 1 impairs clathrin uncoating at synapses and triggers dystrophic changes in dopaminergic axons. Neuron. 93:882–896 e5. 2017.PubMed/NCBI View Article : Google Scholar
19	Kim CY and Alcalay RN: Genetic forms of Parkinson's disease. Semin Neurol. 37:135–146. 2017.PubMed/NCBI View Article : Google Scholar
20	Bellou V, Belbasis L, Tzoulaki I, Evangelou E and Ioannidis JP: Environmental risk factors and Parkinson's disease: An umbrella review of meta-analyses. Parkinsonism Relat Disord. 23:1–9. 2016.PubMed/NCBI View Article : Google Scholar
21	Subramaniam SR and Chesselet MF: Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog Neurobiol. 106-107:17–32. 2013.PubMed/NCBI View Article : Google Scholar
22	Kamat PK, Kalani A, Rai S, Swarnkar S, Tota S, Nath C and Tyagi N: Mechanism of oxidative stress and synapse dysfunction in the pathogenesis of Alzheimer's disease: Understanding the therapeutics strategies. Mol Neurobiol. 53:648–661. 2016.PubMed/NCBI View Article : Google Scholar
23	Filomeni G, De Zio D and Cecconi F: Oxidative stress and autophagy: The clash between damage and metabolic needs. Cell Death Differ. 22:377–388. 2015.PubMed/NCBI View Article : Google Scholar
24	Kim EK and Choi EJ: Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 1802:396–405. 2010.PubMed/NCBI View Article : Google Scholar
25	Kyriakis JM and Avruch J: Mammalian MAPK signal transduction pathways activated by stress and inflammation: A 10-year update. Physiol Rev. 92:689–737. 2012.PubMed/NCBI View Article : Google Scholar
26	Lu N and Malemud CJ: Extracellular signal-regulated kinase: A regulator of cell growth, inflammation, chondrocyte and bone cell receptor-mediated gene expression. Int J Mol Sci. 20(3792)2019.PubMed/NCBI View Article : Google Scholar
27	Schattauer SS, Bedini A, Summers F, Reilly-Treat A, Andrews MM, Land BB and Chavkin C: Reactive oxygen species (ROS) generation is stimulated by κ opioid receptor activation through phosphorylated c-Jun N-terminal kinase and inhibited by p38 mitogen-activated protein kinase (MAPK) activation. J Biol Chem. 294:16884–16896. 2019.PubMed/NCBI View Article : Google Scholar
28	Jiang H, Xing J, Fang J, Wang L, Wang Y, Zeng L, Li Z and Liu R: Tilianin protects against ischemia/reperfusion-induced myocardial injury through the Inhibition of the Ca²⁺/calmodulin-dependent protein kinase II-dependent apoptotic and inflammatory signaling pathways. Biomed Res Int. 2020(5939715)2020.PubMed/NCBI View Article : Google Scholar
29	Jiang H, Ashraf GM, Liu M, Zhao K, Wang Y, Wang L, Xing J, Alghamdi BS, Li Z and Liu R: Tilianin ameliorates cognitive dysfunction and neuronal damage in rats with vascular dementia via p-CaMKII/ERK/CREB and ox-CaMKII-dependent MAPK/NF-κB pathways. Oxid Med Cell Longev. 2021(6673967)2021.PubMed/NCBI View Article : Google Scholar
30	Jiang H, Zeng L, Dong X, Guo S, Xing J, Li Z and Liu R: Tilianin extracted from Dracocephalum moldavica L. induces intrinsic apoptosis and drives inflammatory microenvironment response on pharyngeal squamous carcinoma cells via regulating TLR4 signaling pathways. Front Pharmacol. 11(205)2020.PubMed/NCBI View Article : Google Scholar
31	Mullin S and Schapira AH: Pathogenic mechanisms of neurodegeneration in Parkinson disease. Neurol Clin. 33:1–17. 2015.PubMed/NCBI View Article : Google Scholar
32	Nagatsu T and Nagatsu I: Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): Historical overview and future prospects. J Neural Transm (Vienna). 123:1255–1278. 2016.PubMed/NCBI View Article : Google Scholar
33	Zhu Y, Zhang J and Zeng Y: Overview of tyrosine hydroxylase in Parkinson's disease. CNS Neurol Disord Drug Targets. 11:350–358. 2012.PubMed/NCBI View Article : Google Scholar